UroGen Pharma (URGN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

UroGen Pharma

NasdaqGM•Healthcare•Biotechnology

$43.49+1.75(0.04%)Pre-market

Market Cap

$2.21B

P/S

11.7x

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

How this company scores

WeakMetricSide Score: 47/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (20/25); weakest: Cash & Earnings Quality (8/25).

Profitability11/25

Growth20/25

Balance Sheet & Red Flags8/25

Cash & Earnings Quality8/25

Strengths

Growing revenueCash-backed earningsProfit converts from growthConsistent growth

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 11.7x5y range 2.9x – 11.7x

Currently above its 18-quarter median.

P/B · 21.5x5y range 20.4x – 21.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.21B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $188.73M
Q. Revenue: $72.46M
TTM EBITDA: $-66.34M
TTM Op. Income: $-66.65M
Q. Op. Income: $111,000
TTM Net Income: $-97.64M
Q. Net Income: $-14.35M
EPS: $-0.28
Shares Out.: $50.38M

$188.73M in TTM revenue grew 100.3% YoY, reaching $72.46M last quarter. TTM EBITDA of $-66.34M and TTM operating income of $-66.65M show growth is flowing through to the bottom line. However, net income is negative at $97.64M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 90.9%
EBITDA Margin: 0.3%
Op. Margin: 0.2%
Net Margin: -19.8%

Op. margin of 0.2% is up 171.3% YoY — cost efficiency is improving. Net margin at -19.8% and gross margin of 90.9% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 5 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 11.7x
P/B Ratio: N/A

P/S of 11.7x and P/B of 0.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $252.59M
Cash: $79.13M
Long-Term Debt: $188.73M
Book Value: $-132.40M
D/E Ratio: N/A
Debt/EBITDA: 894.5

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-33.01M
TTM Free Cash Flow: $-159.13M
FCF Margin: -84.3%
FCF / Net Income: 1.6

TTM FCF of $-159.13M on $-33.01M in operating cash flow. The FCF / Net Income ratio of 1.6x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 29% — an improving trend.